Response to Comments: Glucose Monitors – DL33822

The policy removes prior requirements that beneficiaries demonstrate use of a blood glucose meter and perform frequent (>=4/day) self-monitoring to qualify for a continuous glucose monitor. It also expands CGM eligibility to individuals using multiple daily administrations of any insulin, explicitly including inhaled insulin (Afrezza). DME MACs will apply current clinical evidence per CMS guidance when finalizing coverage decisions.

"Continuous glucose monitors (CGMs) may be covered for individuals who use multiple daily administrations of any insulin, including inhaled insulin (Afrezza)."

Sign up to see full coverage criteria, indications, and limitations.